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Hemichorea-hemiballism (HCHB) can be the solely 
presentation of a wide range of non-neurological clinical 
pictures, such as metabolic or hydro-electrolyte derange-
ments. HCHB as the first presentation of type 2 diabetes 
mellitus has been rarely described1-3. 
The case depicted herein reinforces this association 
highlighting that especially in elder patients with new-
ly diagnosed HCHB, non-ketotic hyperglycemia should 
promptly be recognized. 
case
A 70-year-old white man presented with one month history 
of involuntary movements of the left upper and lower limbs. He 
also noticed polyuria and polydipsia for the last 2 months and 
lost 10 kg within this period. His past medical history included 
controlled hypertension and a heart attack three years before. 
He used to take on a regular basis and at the time of presenta-
tion to our emergency department captopril 50 mg per day, hy-
drochlorothiazide 25 mg per day, propranolol 120 mg per day, 
aspirin 200 mg per day, and digoxin 0.25 mg per day. He used to 
be a heavy drinker (stopped 15 years ago) and smoker (stopped 3 
years ago). There was no history of diabetes mellitus, other dis-
eases or exposure to neuroleptic medication. No family history 
of movement disorders was obtained. 
On admission, he was fully alerted and oriented. He had 
HCHB involving his left upper and lower limb with normal mus-
cle strength, but mild hypotonia. The movements were almost 
continuous during wakefulness, and disappeared during sleep. 
Fasting blood glucose was obtained (560 mg/dL) and type 2 dia-
betes mellitus was diagnosed. Glycosylated hemoglobin A1c was 
6.6%. No ketones were detected in urinalysis and urine pH was 
normal. Corrected sodium concentration was 140 mmol/L, and 
estimated serum osmolality was 332 mOsm/L. Other routine 
blood tests including calcium, potassium, magnesium, and phos-
phate concentrations, and thyroid and parathyroid hormone 
tests were normal as well liver and kidney functional status. A 
brain computer tomography (CT) showed a slight hyperdense 
lesion on the right putamen. T1-weighted brain magnetic reso-
nance imaging (MRI) showed a right hyperintense lesion on pu-
tamen with iso-signal intensity on T2-weighted and Flair images. 
With the administration of haloperidol (10 mg per day) and 
glycemia control (10 IU bed time NPH insulin) and 6 mg per day 
glimepiride his movement disorder decreased in severity and 
completely disappeared 15 days after the first medical appoint-
ment. A nine-month re-scan with MRI showed a normal putamen 
without the previously seen hyperintense lesion (Figure). 
The patient signed an informed consent to allow his data 
publication.
discussion
The underlying mechanisms of brain alterations in pa-
tients with non-ketotic hyperglycemia-induced HCHB are 
not known yet, but they have been attributed to base gan-
glia cerebral blood flow reduction, petechial hemorrhage, 
depletion of both GABA and acetylcholine, or metabolic 
acidosis4. Interestingly, among neuronal subtypes, striatal 
medium spiny neurones are highly vulnerable to energy 
depletion and this might explain the predilection for le-
sions situated in the striatum4. In a recent case report 
Figure. MRI scan showing a hyperintense lesion in the right putamen 
on T1-weighted image (left). A nine-month re-scan (right) shows com-
plete disappearance of the putaminal lesion, even after contrast gad-
olinium enhancement. Arrow corresponds to the right putamen. A la-
cunar infarct is also seen on the left thalamic-internal capsular region.
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study, it was suggested that petechial hemorrhage sec-
ondary to erythrocyte diapedesis due to hyperglycemia-
induced blood-brain barrier dysfunction might also have 
a role in the syndrome5. 
Typically, the neuroimaging abnormalities seen in 
patients with HCHB last several months to years disap-
pearing much later than the movement disorder. The 
characteristic features are high signal intensity lesions 
on T1-weighed brain MRI, and these alterations are not 
yet fully understood. There is, however, hyperglycemia-
induced HCHB without MRI abnormalities2, and therefore 
these unique imaging alterations should not be taken as 
a clear-cut surrogate marker for putaminal dysfunction 
associated to an hyperglycemic insult. 
Elder female diabetic patients from East Asian origin 
are more prone to develop HCHB, but whether this is re-
lated to a particular genetic predisposition is still a matter 
of debate. Recently, it was suggested that the presence of 
acanthocytes in circulating peripheral blood might render 
diabetic patients prone to develop HCHB6. In our case we 
did not search for acanthocytes on the peripheral blood 
since a good relief of symptoms was obtained with gly-
cemia control and the use of neuroleptics. 
The prognosis of non-ketotic hyperglycemia-induced 
HCHB is favorable and depends on the prompt identifi-
cation of undiagnosed diabetes or the compensation of 
previously diagnosed patients. Additionally, typical neu-
roleptics and sometimes benzodiazepines are useful in 
the management of the choreic movements. Topiramate7, 
levetiracetan8 and tetrabenazine9 have also been tried in 
selected cases with favorable outcomes. 
We recently reported three other cases (2 men, 1 
woman) of new onset HCHB in elder patients attributed 
to non-ketotic hyperglycemia3. One of these patients, 
similarly to this case, was unaware of having type 2 diabe-
tes mellitus. The mean time for their movement disorder 
to fully recover was approximately 12 days and they all 
took haloperidol in a long-term basis without side effects. 
Two of the patients had concurrent infection (pneumonia 
and meningitis) suggesting that this might play as a trig-
ger factor for HCHB in predisposed patients. The charac-
teristic T1-weigthed hyperintense lesions in the striatum 
were found in all patients especially contralateral to the 
affected limb. Cupidi and coworkers also described a dia-
betic patient mild uremia that developed an acute but 
reversible form of parkinsonism, emphasizing that acute 
extrapyramidal syndromes may occur in diabetic patients 
with concurrent decompensated metabolic diseases and 
that this clinical syndrome is likely independent from ra-
cial and/or genetic variables10.
In conclusion, this case report underscores the non-
ketotic hyperglycemia-induced HCHB syndrome as an 
unusual presentation of type 2 diabetes mellitus, high-
lighting that its recognition and stringent glycemia control 
associated to the use of neuroleptics hasten the patient 
recovery. Moreover HCHB syndrome should be regularly 
included in the differential diagnosis of acute movement 
disorders, especially in the elder population.
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